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1. Introduction 2, Materials and methods 
lndomethacin, a non-steroidal nti-inflammatory- 
agent, is known to interfere with prostaglandin syn- 
thesis by inhibiting the enzyme cyclooxygenase [1,2]. 
This drug can also inhibit the phospholipase A2 of 
rabbit polymorphonuclear leukocytes (PMN) in vitro 
[3]. However, in vitro, indomethacin can block many 
of the responses of rabbit and human PMN elicited by 
the synthetic hemotactic peptide formyl-Met Leu- 
Phe (FMLP), such as aggregation, lysosomal enzyme 
release or superoxide anion generation [4-7]. These 
in vitro effects of indomethacin which do not appear 
to be correlated with its inhibition of cyclooxygenase 
and/or phospholipase A2 activities [5] have not been 
adequately explained [4,5]. 
One possibility not explored, is that indomethacin, 
owing to its hydrophobic nature, interferes with the 
binding of FMLP to its specific receptor present on 
the PMN plasma membrane [8 10]. 
These studies were undertaken to test this hypoth- 
esis directly by using the radiolabelled peptide 
[3H] FMLP. They show that indomethacin s a com- 
petitive and reversible inhibitor of the binding of the 
chemotactic peptide. The concentration f indometh- 
acin which inhibits 50% of the binding of [3HI FMLP, 
7 X 10 -s M, was found to be of the same order of 
magnitude than that which was shown to inhibit 50% 
of the in vitro effects of FMLP [4,5]. We have also 
demonstrated that this effect ofindomethacin is highly 
dependent on the presence of albumin in the incuba- 
tion medium. 
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PMN were isolated from peripheral blood of normal 
human volunteers by means of Ficoll-Hypaque density 
separation ('~98% PMN). After hypotonic lysis of 
erythrocytes, PMN were washed twice and, if not 
stated otherwise, resuspended in Hanks' balanced salt 
solution (HBSS). FMLP was obtained from UCB 
(Brussels) and [all] FMLP (46.4 Ci/mmol) from New 
England Nuclear. Indomethacin and bovine or human 
serum albumin (fraction V) were supplied by Sigma 
(St Louis MO). FMLP was dissolved in DMSO at 
2 X 10 -3 M and diluted in HBSS before use. Indometh- 
acin was dissolved in absolute thanol. 
The radioligand binding assay for [3H] FMLP was 
done as in [10], except hat cells were preincubated 
for 10 min with or without indomethacin before adding 
the labelled peptide. The final concentration f ethanol 
was 5% (v/v). 
3. Results 
Tire direct binding isotherms of [3HI FMLP to 
human PMN at 22°C in the absence and in the pres- 
ence of 10 -4 M indomethacin are presented in rigA. 
They demonstrate hat the drug acts as a competitive 
inhibitior of the binding of [3H] FMLP. In the pres- 
ence of indomethacin the dissociation constant (K d) 
increased from 2.2-7.6 X 10 -8 M. From these data, 
the inhibition constant (Ki) of indomethacin for the 
binding of [3H] FMLP was calculated to be 4 X 10 -s M 
using the equation: 
Ki=I/(K'a/Ka 1)[11] 
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Fig.1. Binding of [3IJ]FMLP to PMN as a function of [3H]- 
FMLP concentration. Binding was measured after 30 min in- 
cubation of PMN (3 X 10 ~ cells) with increasing concentra- 
tion of labelled FMLP at 22°C in HBSS. The non-specific 
binding (measured in the presence of a 1000-fold excess of 
unlabelled FMLP) has been subtracted from each point; 
(e) binding measured in the absence of indomethacin; (~) 
binding measured in the presence of 10 -4 M indomethacin; 
(insert) data plotted according to Scatchard analysis. Each 
point is the mean of triplicate determinations in a single 
experiment. Similar results were obtained in 2 separate xper- 
iments. 
where K a and K '  a are the dissociation constants  of  
[al l]  FMLP binding in the absence and presence of  
indomethac in ,  respectively, and I is the concentrat ion  
of  the drug. The Scatchard plots presented in the insert 
o f  fig. 1 show that  the 3 X 106 PMN can bind 275 fmol 
[3H] FMLP which represent ~50 000 binding sites/ 
cell. In [10] we had found a value of  40 000 binding 
sites/cell. This di f ference can be explained by the fact 
that  this t ime the binding exper iments  were performed 
in the presence of  5% (v/v) ethanol ,  which increases 
the number  of  available b inding sites for [3t1] FMLP 
on human PMN (not  shown).  Similar qualitative results 
have been found wi th  rabbit  neutrophi ls  [12]. 
Fig.2 shows the effects of  various concentrat ions  
o f indomethac in  on the binding of  2 × 10 -8 M [3H]- 
FMLP. The concentrat ion  required for hal f -maximal 
inh ib i t ion was determined to be 7.1 × 10 -s M, and 
K i was calculated, assuming compet i t ive inhib i t ion by 
the drug at the [3HI FMLP receptor,  f rom the equat ion:  
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Fig.2. Effect of various concentrations of indomethacin on 
the binding of [3H]FMLP. PMN (3 × 106 cells)were first 
preincubated with or without indomethacin for 10 rain at 
22°C in ttBSS. [3H]FMLP (2 × 10 -8 M) was then added and 
the incubation was continued for another 30 rain. The amount 
of [31tJFMLP bound was then determined as in section 2. 
The non-specific binding has been subtracted from each point 
and inhibition of binding is expressed in terms of% inhibition 
of specific binding of labelled ligand. Each point is the mean 
of 3 different determinations done in duplicate: (~) PMN 




Albumin  concent ra t ion  (mglml}  
Volume 132, number 1 FEBS LETTERS September 198l 
Fig.3. Effect of the presence of bovine serum albumin on the 
inhibition of the binding of [3H]FMLP due to indomethacin. 
Binding of [all] FMLP was measured as in fig.2 in the presence 
of 10 -4 M indomethacin i  HBSS containing different concen- 
trations of bovine serum albumin. Each point is the mean of 
3 different determinations done in duplicate. 
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where ICso = 7.1 × 10 -s M, S is the concentration f
[3HI FMLP (2 X 10 -8 M)and K a is the dissociation 
constant for the binding of [3H] FMLP (2.2 × 10 -8 M). 
In these conditions K i = 3.7 X 10-s M. This value is, 
as expected, in close agreement with that determined 
from the experimental design of fig.1. PMN which 
were preincubated for 10 min with indornethacin and 
then washed before addition of [3HI FMLP bind the 
same amount of tritiated peptide as PMN incubated 
in HBSS alone (fig.2). 
Fig.3 shows that the inhibition of binding of [3H]- 
FMLP produced by 10-4 M indomethacin s highly 
dependent on the presence of bovine serum albumin, 
being almost otally blocked at 2% (w/v) BSA. Very 
similar results were found with human albumin (not 
shown). 
4. Discussion 
In [4- 7], the anti-inflammatory drug, indometh- 
acin, inhibited, in vitro, the responses of rabbit and 
human PMN elicited by the synthetic hernotactic 
peptide FMLP. The level of indomethacin giving half- 
maximal inhibition was between 10-s-- 10-4 M 
depending on the response tested. These findings led 
to the inference that the inhibitory effect ofindometh- 
acin was due to its already known action on the 
enzymes cyclo-oxygenase and phospholipase A2 [1-3] 
and to the conclusion that the intermediates in the 
synthesis of prostaglandins were important in the 
action of the peptide FMLP on PMN. However, as 
the concentrations of indornethacin necessary to 
inhibit the action of FMLP were higher than that 
which inhibited cyclo-oxygenase and since, in the same 
conditions, another anti-inflammatory drug, aspirin, 
was not inhibitory this interpretation was not shared 
[51. 
Thus, to tentatively explain the in vitro inhibitory 
effect of indomethacin on FMLP actions, we have 
explored another hypothesis which was that indometh- 
acin could act by impeding the binding of FMLP to 
receptors which had been demonstrated to exist on 
the plasma membranes ofhuman PMN [9,10]. 
These data show without any doubt hat indometh- 
acin is indeed an inhibitor of [3HI FMLP binding on 
human PMN. They indicate that our hypothesis was 
relevant since the concentration findomethacin which 
gives 50% inhibition of binding is the same as that 
found to inhibit 50% of the effects of FMLP [4,5]. 
Moreover, indornethacin does not inhibit the binding 
of [3H] FMLP when albumin is present in the incuba- 
tion medium [4,5]. The most probable xplanation 
for this last result is that indornethacin has a greater 
affinity for albumin [13] than for PMN and that it 
no longer acts when bound to the protein. 
Our hypothesis  strengthened bythe data in [14]. 
They found that two other anti-inflamrnatory drugs, 
phenylbutazone and sulfinpyrazone possess in vivo, as 
well as in vitro, potent antagonistic properties against 
FMLP-induced PMN alteration in rabbits, and in vitro 
in human. They found also that both drugs were inhib- 
itors of the binding of [3H] FMLP on human PMN with 
ICso of 1.97 × 10 -4 M and 7.2 × 10 -5 M, respectively. 
lndomethacin did not inhibit the binding of [31-t]- 
FMLP in vitro [14]. However, this result is not sur- 
prising since 100% autologous heat-inactivated plasma 
was used in the radioligand binding assay [14]. 
Our hypothesis further strengthened bythe fact 
that indornethacin is not an inhibitor when the 
responses of PMN (lysosomal enzyme release, aggrega- 
tion), are elicited by another chernotactic factor, C5a, 
[4,5,13 ] which binds to PMN at receptor sites distinct 
to that of FMLP [15]. 
From this study we cannot explain the mechanism 
by which indornethacin i terferes with the binding of 
FMLP to the human neutrophil. This could involve 
competition for a common receptor site or binding of 
the drug at separate sites such that the binding of 
FMLP to its proper sites would be impeded. In favor 
of receptor identity for FMLP and indornethacin are 
the observations that the other two anti-inflammatory 
drugs [12] suppress the responses of PMN ellicited by 
pepstatin. This pentapeptide is a potent chernotaxin 
for human PMN and shares a common receptor with 
FMLP on these cells [ 16]. It does so despite its primary 
structure being unrelated to that of FMLP [16]. How- 
ever FMLP, pepstatin and indornethacin have one fea- 
ture in common, they are all very hydrophobic. This 
suggests that one part of the receptor site for FMLP is 
constituted by an hydrophobic pocket which would 
be able to bind hydrophobic molecules of unrelated 
primary structures. It is interesting to note that if the 
K d for the binding of FMLP to its receptor is around 
10 -8 M [10] the K i for both pepstatin [16] and indo- 
rnethacin are around 10 -s M. 
While this manuscript was in preparation, indometh- 
acin was reported to inhibit the binding of the peptide 
hormone angiotensin to its receptors in bovine urn- 
bilical artery with anlDso of 1.6 X 10 -4 M [17]. 
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These data demonstrate that indomethacin,  in the 
absence of  albumin, is a competit ive inhibitor of  the 
chemotact ic peptide FMLP for its binding on human 
PMN. This finding, which adds a new role for indo- 
methacin, is the most probable explanation for in vitro 
inhibit ion, by the drug, of  the responses of  PMN stim- 
ulated by FMLP. 
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